

Prescriber Criteria Form

Lenvima 2024 PA Fax 1248-A v1 010124.docx  
 Lenvima (lenvatinib)  
 Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.  
 Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673**.  
 Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process.  
 When conditions are met, we will authorize the coverage of Lenvima (lenvatinib).

Drug Name:  
 Lenvima (lenvatinib)

<b>Patient Name:</b>		
<b>Patient ID:</b>		
<b>Patient DOB:</b>	<b>Patient Phone:</b>	
<b>Prescriber Name:</b>		
<b>Prescriber Address:</b>		
<b>City:</b>	<b>State:</b>	<b>Zip:</b>
<b>Prescriber Phone:</b>	<b>Prescriber Fax:</b>	
<b>Diagnosis:</b>	<b>ICD Code(s):</b>	

Please circle the appropriate answer for each question.			
1	Does the patient have a diagnosis of medullary thyroid carcinoma? [If yes, then no further questions.]	Yes	No
2	Does the patient have a diagnosis of differentiated thyroid carcinoma (follicular, papillary, or Hurthle cell)? [If no, then skip to question 4.]	Yes	No
3	Does the patient have disease that is not amenable to radioactive iodine therapy and the disease is unresectable, locally recurrent, persistent, or metastatic? [No further questions.]	Yes	No
4	Does the patient have a diagnosis of advanced, relapsed, or stage IV renal cell carcinoma? [If yes, then no further questions.]	Yes	No
5	Does the patient have a diagnosis of hepatocellular carcinoma? [If no, then skip to question 7.]	Yes	No
6	Is the patient's disease unresectable or inoperable, local, metastatic, or with extensive liver tumor burden? [No further questions.]	Yes	No

7	Does the patient have a diagnosis of endometrial carcinoma? [If no, then skip to question 12.]	Yes	No
8	Is the disease advanced, recurrent, or metastatic? [If no, then no further questions.]	Yes	No
9	Will the requested drug be used in combination with pembrolizumab? [If no, then no further questions.]	Yes	No
10	Has the patient experienced disease progression following prior systemic therapy? [If no, then no further questions.]	Yes	No
11	Is the patient a candidate for curative surgery or radiation? [No further questions.]	Yes	No
12	Does the patient have a diagnosis of thymic carcinoma?	Yes	No

Comments:	
-----------	--

By signing this form, I attest that the information provided is accurate and true as of this date and that the documentation supporting this information is available for review if requested by the health plan.

<b>Prescriber (or Authorized) Signature:</b> _____	<b>Date:</b> _____
--	--------------------